Baxter BioPharma Solutions

BioPharma Solutions, a business unit of Baxter, collaborates with pharmaceutical companies to provide contract manufacturing form/fill/finish for injectables, backed by 85 years of parenteral experience. With broad drug category expertise, including oncology products, biologics, ADCs and vaccines, we offer a variety of sterile dosage forms, including prefilled syringes, liquid vials, lyophilized vials, cartridges, and cost-saving diluents for reconstitution. Whether you face formulation challenges, clinical supply hurdles, surges in demand due to market fluctuations, risk mitigation concerns, or patent expiry challenges, we offer tailored, versatile solutions—from clinical to commercial—designed to meet complex and traditional sterile manufacturing challenges.

Share
One Baxter Parkway Deerfield, IL 60015
Tel: 1-800-4-Baxter

Download Content

Building the Future – Using Simulation Effectively
This case study provides an in-depth look at Baxter BioPharma Solutions’ latest expansion at their Halle, Germany cytotoxic facility, offering insight on: • Handling of complex expansion projects • Elements of process design • Application of different simulation and visualization tools • Innovations for manufacturing of parenterals • Effective team building
Pharmaceutical Development for ADCs: Not as Simple as ABC
Provides an overview of: • ADC structure and function • The development process • Lyo cycle optimization
Best Practices in Formulation and Lyophilization Development: Proteins, mAbs and ADCs
The ultimate goal of formulation development is a stable product. A well-designed product development plan can develop a phase 1 product quickly, while laying the foundation for commercial product success.
A Risk Management Approach to Prefilled Syringe Selection for Biotechnology Products
Prefilled syringes are becoming an increasingly attractive option for complex biotechnology products, not least because of the savings in product volume compared to vials. There is now a wide range of options to suit different requirements which can make product selection a challenge. Wendy Saffell-Clemmer, Director of Research at Baxter Biopharma Solutions, looks at what advances are currently being made.
Application of QbD and QRM to Analytical Method Validation
A Case Study of a Stability-Indicating Method for Protopam

PharmTech News Articles

FDA issued a warning letter to Cixi Zhixin Bird Clean-Care Product Co., Ltd for violations of cGMP for finished pharmaceuticals.

The company announced an investment in a new facility in Dundalk, County Louth, Ireland.

Pharmco Laboratories received an FDA warning letter for significant violations of CGMP for finished drugs and APIs at its Florida, US facility as well as misbranding of over-the-counter (OTC) acne and sunscreen drug products.

Novo Nordisk entered a research collaboration with the University of Oxford focused on Type 2 diabetes.